adtestbench Higgsfield

AI news · OpenAI · life sciences

OpenAI buys Orchestra Bio to manage drug development work

The start-up’s AI agents track budgets and trial schedules for drugmakers, and its team joins Rosalind, OpenAI’s life sciences unit. Terms were not disclosed.

By Alexandre S. , 05:45 UTC

OpenAI said on Tuesday 20 October 2026 that it has bought Orchestra Bio, a San Francisco start-up founded in 2022. Orchestra makes AI agents, programs that take a goal and carry out the steps on their own, for drug companies. Neither side gave a price. The start-up had raised about $20 million, with Andreessen Horowitz and 8VC among its backers, TechCrunch reports.

Retro-futurist illustration: a striped sunset over a grid horizon under a starry sky, with a window motif standing on the horizon.
Drawn by adtestbench from “OpenAI acquires startup Orchestra Bio to beef up its biotech business”,

The agents handle the logistics around a drug programme, from budgets to clinical trial schedules. Take a failed manufacturing batch: the agents trace the knock-on delays and draft options, and a person still picks one, Decrypt reports. OpenAI says a new medicine takes up to 15 years to reach US approval.

Rosalind, the biology unit OpenAI started in April, takes in Orchestra’s staff. Moderna and Novo Nordisk already use its tools, SiliconANGLE reports. OpenAI has not said when the agents reach customers. Anthropic made a similar move in April, paying about $400 million for Coefficient Bio.

With Orchestra, OpenAI’s Rosalind now covers the budgets and timetables of a drug programme as well as the science.